In the absence of a comparative study versus ERBITUX, VECTIBIX does not provide an improvement in actual benefit (non-existent IAB, V) in the treatment of wild-type KRAS metastatic colorectal cancer :
- in first-line in combination with FOLFOX,
- in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
Listen
